Texas road trip

These are the Houston companies headed to MassChallenge Texas in Austin

Natalie Harms
May 24, 2019, 2:07 pm
A handful of Houston startups will be bouncing back and forth to Austin for the second annual MassChallenge Texas accelerator. Getty Images

It's the second cohort for Boston-based MassChallenge Texas in Austin, and this year's 74 selected finalists are well represented by Houston.

"Coming from an extremely competitive application pool, the startups in our second Austin-based cohort represent an incredibly high bar of creativity and talent, all of who are poised to make an impact," says Mike Millard, managing director of MassChallenge Texas, in a release. "This year's program will offer the finalists innovation at scale with direct access to resources through our programs in Houston and Austin, and our community around the state. Through these channels, startups will have more opportunities to test and validate their ideas with partners while creating meaningful engagements to help them get to pilot or pivot as fast as possible."

While there is the upcoming MassChallenge Texas inaugural Houston cohort, these seven companies opted for a spot in the Austin-based cohort where the stakes are higher and cash prizes are on the line — $500,000, the largest equity-free cash prize in Texas, to be precise. (Houston's inaugural set of prizes reportedly don't included money.)

These are seven of the Houston-related companies that will be trekking back and forth to Austin from June until October.

crewcollar

Getty Images

It's crewcollar's mission to optimize hiring for industrial and blue-collar jobs, simplifying the entire process from curated job posts to paperwork filing. The company is based just outside of Houston in Missouri City.

"We are super excited to be joining MassChallenge Texas, and know that this experience will help us take it to the next level," says M. Siler, CEO and founder, in a release.

GotSpot Inc.

Courtesy of GotSpot

Houston-based GotSpot is Reda Hicks solution to finding temporary space quickly and easily — in a way that benefits all sides of the transaction. The model is like AirBnb, but for retail, meeting, and even emergency space. The corporate lawyer has grown the platform over the past few years and the MassChallenge opportunity is another move in the right direction. Click here to read more about Hicks and GotSpot.

Grant Source

Photo via grantsourceapp.com

Grant Source is like the magic genie to help organizations find funding through grants and opportunities. The Houston startup has a database of opportunities and can help match businesses with appropriate grants to apply to — all within the Grant Source mobile app.

Guzo

Getty Images

Guzo is the tool every traveler has dreamed up. The Houston-based app connects travelers — not just in the planning phase — but throughout the travel process. The company was created by two brothers — Joshua and Gordon Taylor — and is the recreation of Croozen, formerly a long-distance carpool app.

"One of the things that got Gordan and I excited in the beginning of Croozen was just the idea of someone else in the car with you and that shared experience," Joshua Taylor tells InnovationMap in a previous interview about revamping Croozen as Guzo. "Looking past that, just being focused on the car was hindering us. Let's divorce the car and focus on travel as a whole."

Lazarus 3D

Photo via laz3d.com

Practice makes perfect, and surgeons should be as close to perfect as possible, right? Lazarus 3D uses 3D printing to make realistic body parts and organs so that surgeons can rehearse their surgeries before ever slicing into a patient. The company is conveniently located in the Texas Medical Center.

Pilot Plus

Photo via pilotplus.com

The trucking industry needs a rebrand. It's a tireless job that's go-go-go, and the unappealing nature of the career isn't ideal. Pilot Plus puts the humanity back in the process that benefits the driver and makes for bragging rights for the company employing the trucker. The logistics company allows for a system of drivers that work together for the long haul so that drivers can actually spend time resting in their own homes.

Topl

Courtesy of Topl

Topl's MassChallenge bio lists their HQ in the Netherlands, but the blockchain startup founded by three Rice University alumni has some of its operations right here in town. Topl has a goal of using blockchain technology to connect the dots and enhance transparency in various applications from retail to even being able to track the success of investments or scholarships.

"We are a generation that wants a story," Kim Raath, president at Topl, tells InnovationMap in a previous interview. "We want an origin, and don't want to be fooled. And, because you might be able to reduce the cost by having this transparency, you might be able to bring down the cost on both sides."


austin texascrewcollargotspotreda hicksgrand sourceguzolazarus 3dpilot plustoplkim raathmasschallenge texas

Trending News

guest column

Houston innovator explores importance of belonging within the modern workforce

 
 

Promoted

freshly funded

Rice researchers score $45M from NIH for cancer-fighting tech

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

From Your Site Articles
Omid VeisehReginald DesRochesRice UniversityARPA-Hamir jazaerithorhammrbiotechnational institutes of health

Trending News

guest column

Houston innovator explores importance of belonging within the modern workforce

 
 

Promoted